Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brenetafusp
- Development stage
- Phase 3
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Brenetafusp (IMC-F106C) is a first-in-class, soluble bispecific T-cell receptor (TCR) therapeutic, part of the Immune mobilizing monoclonal T-cell receptor Against Cancer (ImmTAC) platform developed by Immunocore. It is designed to target the PRAME (Preferentially expressed Antigen in Melanoma) protein, specifically the PRAME peptide presented by the HLA-A*02:01 MHC allele. The molecule consists of an affinity-enhanced TCR fused to an anti-CD3 single-chain antibody fragment (scFv). By binding to PRAME-positive cancer cells and simultaneously engaging CD3 on T-cells, brenetafusp facilitates the formation of an artificial immunological synapse, leading to T-cell activation and the subsequent lysis of the tumor cells. It is currently being investigated in clinical trials for various solid tumors, including cutaneous melanoma, uveal melanoma, and non-small cell lung cancer.
- Brand names
- brenetafusp
- Other names
- brenetafusp-alphaPRAME-A2 ImmTACPRAME-A-2 ImmTACPRAME-A 2 ImmTAC
02
Targets
CD3 (T-cell surface glycoprotein CD3)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on brenetafusp.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brenetafusp.